A dietary supplement is defined as a product taken by mouth containing a dietary ingredient intended to supplement the diet. Dietary ingredients include vitamins, minerals, herbs or other botanicals, and amino acids.
Select an Issue
Dietary Supplement Resource Library
Explore our list of resources to learn more about the dietary supplement category and how it is regulated by the U.S. Food and Drug Administration (FDA) and Federal Trade Commission (FTC).
The Dietary Supplements Access Act of 2023 is bipartisan legislation intended to give American consumers increased flexibility to best determine how to use their pre-tax dollars to stay healthy.
It’s a common misconception that the dietary supplements category is not regulated, when in fact it is regulated by multiple government agencies, with manufacturers and retailers also managing responsibility throughout the process.
Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.
Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.
This past week, the House of Representatives adjourned for its annual August recess, although the House Democratic Leadership indicated that members would be called back sometime in August, should the Senate pass the Inflation Reduction Act of 2022.
Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released a statement today in response to a recent report published in the Journal of the American Medical Association (JAMA).
When it comes to self-care solutions, pharmacists can be an overlooked resource. Today we speak with Dr. Wendy Mobley-Bukstein, Associate Professor of Pharmacy Practice at Drake University about how pharmacists are playing bigger and critical roles in the self-care ecosystem.
Here are the Federal Register notice summary excerpts that might be of interest to you or others within your organization. Please see notices for complete details.
CHPA believes that FDA’s issuance of the 2022 Draft Guidance is premature. Instead, FDA’s priority should be on finalizing the 2016 Draft NDI Guidance and clarifying unanswered questions about the scope and applicability of the NDI notification requirement.
